Conditions of Abstract Submission

• Abstract submitted should follow the criteria and theme of the Excellence Case Sharing Award for the year.
  
• Abstracts are to be submitted using the ECSA Abstract Submission Template.
• Abstracts must be submitted online via the ECSA website. Abstracts submitted by fax, email, or post will NOT be accepted.
• Abstracts must be submitted before the deadline. The online submission system will close at midnight GMT on 1 September 2026.
• After submitting your abstract, you will receive an email confirmation that your abstract has been received after 2 working days.
• The authors may submit one or more case abstracts. Each submission should describe one case subject. As such, each institution may have more than one participating author. However, please do not submit multiple copies of the SAME abstract.
• Authors can submit your own case study, or you can submit a case study on behalf of a colleague or your team. The presenting author can be the first author or the coauthor. The coauthor's full name and institution MUST have been listed during the online abstract submission
• Abstracts must be submitted in English with a quality suitable for publication.
  
• Authors must be able to present and respond to questions in English at the Grand Final in the event their abstract is selected as a finalist. The presenting author can be the first author or the coauthor. The coauthor's full name and institution MUST have been listed during the online abstract submission.
• By submitting an abstract, the author consents to giving Aesculap Academy and B. Braun Melsungen AG permission to publish the abstract in the Excellence Case Sharing Supplement and to share the respective cases of the authors herewith.
• Withdrawal of abstracts can only be accepted by the organiser if notified in writing and subsequently confirmed by the organiser secretariat. Authors may choose to withdraw from participating in the ECSA competition no later than 14 days after the abstract submission deadline.
• Abstracts must be submitted BEFORE the deadline to be reviewed for inclusion in the award.

• Limited to 25 words.
• Needs to be in CAPITAL LETTERS.
• No full stop at the end.
• Should clearly indicate the nature of the study.

Content

• Limited to 500 words.
• All abbreviations must be defined in the first use. Statements such as “results will be discussed” or “data will be presented” cannot be accepted.
  
• The 7 criteria above needs to be well covered within the abstract.
• Aim: Clearly state the purpose of the abstract.

H – History

• Provide the background of the case, aetiology and age of the wound. 
• Include relevant medical conditions (e.g., diabetes, poor circulation), surgical background (e.g. haemostasis, neurovascular), medications, allergies, nutrition, lifestyle factors (e.g. smoking or mobility) and social history.

E – Examination

• Review the subject holistically.
• Describe the subject’s wound presentation using the TIMERS framework components.
• Include the subject’s vital signs, any suspected biofilm, extent of tissue damage, contamination risk, infection concerns, and factors contributing to delayed healing. 
• Include the subject’s pain experience using a validated pain score tool. Provide weekly details consecutively for minimal total of 4 weeks in the table provided in the abstract submission template of pain scores. 

I – Investigation 

• Provide details of investigations ie laboratory (e.g. blood tests, wound cultures), imaging (e.g. x-ray, CT) and vascular assessment.

D – Diagnosis

• Determine the diagnosis.
• Provide clinical reasoning to the chosen management plan using supporting guidelines/consensus document/best practices for the subject’s wound type and healing barriers.

I – Intervention and Indicators

• Specify Prontosan® products used for wound bed preparation and note any additional advanced therapies applied. Describe why Prontosan® products suited the wound and subject’s needs.
• Describe the cleansing, debridement, dressing choices, and antimicrobial or biofilm‑targeting steps.
• Describe the pain‑management methods, both pharmacological and non-pharmacological used and explain how these methods help improve the subject’s recovery.
• Record measurable outcomes: wound size, slough/biofilm, pain scores, mobility/function, and the subject’s treatment tolerance
• Summarize key benefits: wound readiness to closure, pain, comfort, healing, quality of life, and overall impact of the interventions on the outcomes.
• Provide an overall conclusion of the case subject

This section MUST be filled and included in your ECSA Abstract:

• TIMERS Framework, Wound Size Measurements and Pain Scores.
• Resource Utilisation Data to demonstrate prudent resource utilization.
• Wound Images. Please state the date accordingly.

Optional: You may discuss the resource utilization of cleansing solution, gels, dressings, medication (e.g., antibiotics, analgesics), length of stay, cost-of-care setting, disability and prevention of complications in this section. 

• The independent expert panel will review the abstract. 
• Selected finalist will be notified in October 2026, approximately 2 months prior to the Grand Final.
• It is the responsibility of all authors that case studies are performed with respect to national legislation, international legislation and ethical guidelines with regards to both humans and animals. The organiser reserves the right to reject any submitted abstract that is believed to have violated these principles.

The following terms apply: 

• Abstract cannot be modified or corrected after the final submission (by the deadline). Accepted abstracts will be published exactly as submitted. Please ensure all information is correct at the point of submission.
  
• Submission of the abstract constitutes the consent of the author and co-author(s) to publication (e.g., award booklet, programmes, other promotions, etc.)
  
• The abstract submitter warrants and represents that he/she is the owner or has the rights to all the information and content (“Content”) provided to ECSA and Asia Pacific Asculap Academy (hereafter: “The Organiser”). It is the responsibility of the abstract owner to ensure that the publication of the abstract does not infringe any third party rights including, but not limited to, intellectual property rights.
  
• By submitting the abstract, authors grant the organisers a royalty-free, perpetual, irrevocable non-exclusive license to use, reproduce, publish, translate, distribute, and display content therein.
  
• The organisers reserve the right to remove any publication of an abstract which does not comply with the above.
  
• The abstract author is responsible for informing the other co-authors regarding the abstract status.